AACR: Little Apexigen steals the show with their CD40/Opdivo cocktail as AACR gets underway
Now that the pioneer PD-1 checkpoints have hit the market and started earning their billions, researchers in oncology are focused on the next big thing …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
